With respect, I think you are making a bit of confusion here.
The “Cost of Risk” is the aggregate Impairment Charge on Customer Loans, expressed as a percentage of Total Loans. It has nothing to do with the interest charged to customers on those loans.
By way of illustration (looking at the left-hand side of your attachment, and using figures as of March 31st 2019):
Total Customer Loans: 72,600m GBP
Net Cost of Risk: 21bps (annualised)
Gross Cost of Risk: 26bps (annualised)
Net Impairment charge: 72,600m*0.0021%*0.5 = 76m GBP (vis-a-vis 77m GBP as reported, due to rounding errors)
Gross Impairment charge: 72,600m*0.0026%*0.5 = 94m GBP
If you now look at the right-hand side of your attachment, you can add up the individual gross impairment charges for the different types of loans, and check that the total corresponds to the Gross Impairment Charge calculated above:
Mortgages: 60,500m*0.0001%*0.5 = 3m GBP
SME: 7,600m*0.0055%*0.5 = 21m GBP
Unsecured: 4,500m*0.0317%*0.5 = 71m GBP
Total: 95m GBP (vis-a-vis 94m GBP calculated above, due to rounding errors).
If you want to see the actual yield breakdown by asset type (reflective of the interest charged to customers) you have to look at slide 12 in the same presentation (see picture below):
As you can see, the average annualised yield as of March 2019 was 4.17% on SME loans and 7.65% on Unsecured loans, which is quite a bit higher than the figures you indicated.
Hope this helps, cheers.
- Forums
- ASX - By Stock
- VUK
- Ann: CYBG PLC Third Quarter 2019 Trading Update
Ann: CYBG PLC Third Quarter 2019 Trading Update, page-158
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add VUK (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Will Souter, CFO
Will Souter
CFO
Previous Video
Next Video
SPONSORED BY The Market Online